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Abstract: Vascular dementia (VaD) is the second most common form of dementia and is currently defined as a
cerebral vessel vascular disease leading to ischemic episodes. Apolipoprotein E (apoE) gene polymorphism has
been proposed as a risk factor for VaD, however, to date there are few documented post-mortem studies on apoE
pathology in the VaD brain. To investigate a potential role for the apoE protein, we analyzed seven confirmed cases
of VaD by immunohistochemistry utilizing an antibody that specifically detects the amino-terminal fragment of apoE.
Application of this antibody, termed N-terminal, apoE cleavage fragment (nApoECF) revealed consistent labeling
within neurofibrillary tangles (NFTs), blood vessels, and reactive astrocytes. Labeling occurred in VaD cases that had
confirmed APOE genotypes of 3/3, 3/4, and 4/4, with respect to NFTs, staining of the nApoECF co-localized with
PHF-1 and was predominantly localized to large, stellate neurons in layer II of the entorhinal cortex. Quantitative
analysis indicated that approximately 38.4% of all identified NFTs contained the amino-terminal fragment of apoE.
Collectively, these data support a role for the proteolytic cleavage of apoE in the VaD and support previous reports
that APOE polymorphism is significantly associated with susceptibility in this disease.
Keywords: Vascular dementia, apoE, apolipoprotein E, neurofibrillary tangles, PHF-1, immunohistochemistry,
plaques, astrocytes

Introduction
Vascular dementia (VaD) is currently the second leading cause of dementia in the USA, only
trailing Alzheimer’s disease (AD) [1]. Diagnosing
VaD is often difficult owing to the common cooccurrence of VaD together with Alzheimer’s
disease (AD), with an estimated 25-80% of all
dementia cases showing mixed pathologies [2].
An additional confounding factor is that there
are currently no widely accepted neuropathological criteria for VaD [3]. VaD is classified as a
cerebral vessel vascular disease characterized
by both large and small infarcts, lacunes, hippocampal sclerosis, and white matter lesions
[4]. The cognitive decline associated with VaD
is thought to be the result of cerebral ischemia secondary to the vascular pathologies
aforementioned.
Behaviorally, patients with VaD show loss in
executive functions as an initial symptom,
whereas in AD memory loss is often associated
with the earliest known symptoms. Other important symptoms of VaD include confusion, lan-

guage deficits, restlessness and agitation, gait
disturbances, and depression [5]. VaD predominantly affects patients with cardiovascular risk
factors including hypertension [6, 7], hyperlipidemia [8], atherosclerosis [9], and diabetes [1012]. Stroke is also an important risk factor for
dementia [13, 14] and the most common stroke
subtype associated with VaD is lacunar stroke
[15].
Human apolipoprotein E (apoE) is polymorphic
with three major isoforms, apoE2, apoE3, and
apoE4, which differ by single amino acid substitutions involving cysteine-arginine replacements at positions 112 and 158 [16]. In AD,
inheritance of the APOE4 allele greatly increases risk up to 10 fold if both alleles are present
[17]. Human apoE has a major function in the
CNS as a cholesterol transporter and therefore,
would seem to be a logical risk factor for VaD.
The loss of apoE function perhaps following proteolytic cleavage is thought to be one potential
mechanism by which apoE4 confers disease
risk in AD [18]. However, whether apoE4 con-
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in 10% methanol to block endogenous peroxiCase Age Sex PMI ApoE Genotype NPD Braak and Braak Plaque Stage
dase activity. Sections
1
83 M 3.75
3/4
VaD
Stage 1
Stage A
were subsequently wa2
75
F 10.5
3/3
VaD
Stage 2
None
shed in TBS with 0.1%
3
83 M 12.4
4/4
VaD
Stage 3
None
Triton X-100 (TBS-A) and
4
74 M 2.6
3/4
VaD
Stage 2
Stage A
then blocked for thirty
5
73 M 4.3
3/3
VaD
Stage 0
None
minutes in TBS-A with
6
88 M 9.9
3/4
VaD
ND
Stage A
3% bovine serum albu7
85
F
3.4
3/3
VaD
Stage 3
Stage B
min (TBS-B). Sections
were further incubated
PMI, postmortem interval in hours; NPD, neuropathological diagnosis, ND, not Determined.
overnight at room temperature with the nApofers a similar risk for the VaD is currently unclear
ECF antibody. Following two washes with TBS-A
and despite the large number of studies examand a wash in TBS-B, sections were incubated
ining whether harboring apoE4 is a risk factor
in anti-rabbit or mouse biotinylated anti-IgG (1
for VaD, an exhaustive literature search failed
hour) and then in avidin biotin complex (1 hour)
to yield a single study examining apoE4 pathol(ABC, Elite Immunoperoxidase, Vector Laboraogy in the post-mortem VaD brain. The purpose
tories, Burlingame, CA, USA). The primary antiof the present study was to determine the
body was visualized using brown DAB substrate
extent of apoE distribution in VaD using both
(Vector Laboratories).
full-length antibodies to apoE as well as an in
Immunofluorescence microscopy
house antibody that specifically detects the
amino-terminal fragment of apoE [19]. Three
Primary antibodies utilized included the
consistent findings were observed using our
nApoECF (rabbit, 1:100), PHF-1 (mouse monocleavage apoE antibody in the VaD brain and
clonal, 1:1,000), anti-apoE4 C-terminal (rabbit,
included labeling within NFTs, blood vessels,
1:100), anti-apoE4 N-terminal (rabbit, 1:500),
and reactive astrocytes. These findings sugand anti-Ab mAb 1560 (clone 6E10, 1:400).
gest a potential role for apoE in contributing to
The anti-Ab mAb 1560 (clone 6E10) was purthe disease process underlying VaD.
chased from Covance (Dedham, MA). The antiapoE4 C-terminal rabbit polyclonal antibody
Material and methods
was purchased from Abgent (San Diego, CA).
Immunohistochemistry
The anti-apoE4 N-terminal rabbit polyclonal
antibody was purchased from Aviva Systems
Autopsy brain tissue from seven neuropathoBiology Corp. (San Diego, CA). PHF-1 was a genlogically confirmed VaD cases were studied.
erous gift from Dr. Peter Davies (Albert Einstein
Case demographics are presented in Table 1.
College of Medicine, Bronx, NY).
Fixed hippocampal tissue sections used in this
Immunofluorescence studies were performed
study were provided by the Institute for Memory
by incubating sections with primary antiboImpairments and Neurological Disorders at the
dies overnight at a room temperature, followed
University of California, Irvine. Free-floating 40
by secondary anti-rabbit or mouse biotinylated
μm-thick sections were used for immunohistoanti-IgG (1 hour) and then in ABC (1 hour).
chemical studies as previously described [20].
Visualization was accomplished by using a tyraNo approval from Boise State University
mide signal amplification kit (Molecular PrInstitutional Review Board was obtained due to
obes, Eugene, OR) consisting of Alexa Fluor
the exemption granted that all tissue sections
488-labeled tyramide (green, Ex/Em = 495/
were fixed and received from University of
519). To visualize beta-amyloid staining, secCalifornia, Irvine. Sections from the hippocamtions were pretreated for 5 minutes in 95% forpus were selected for immunohistochemical
mic acid. For immunofluorescence co-loanalysis.
calization studies, antigen visualization was
For single labeling, all sections were washed
accomplished using an Alexa fluor 488-labeled
with 0.1 M Tris-buffered saline (TBS), pH 7.4,
tyramide (green, Ex/Em = 495/519) for one
and then pretreated with 3% hydrogen peroxide
label and streptavidin Alexa fluor 555 (red, Ex/
Table 1. Case Demographics
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Figure 1. Localization of an amino-terminal fragment of apoE in vascular disease. Application of the nApoECF
antibody in hippocampal tissue sections from VaD cases revealed labeling predominantly within NFTs (arrows, A),
blood vessels (B), and reactive astrocytes (C). For Panel A, Case #7 was utilized, which had an APOE genotype of
3/3. Representative staining within blood vessels indicated a punctate labeling pattern following application of
the nApoECF antibody (B, Case #5, APOE genotype, 3/3). For Panel C, Case #2 was use, which had a confirmed
APOE genotype of 3/3. (D) Double-label immunofluorescence experiment utilizing the nApoECF antibody (arrows,
green) together with Hoechst nuclear staining (arrowheads, blue) confirmed the punctate, irregular staining pattern
of nApoECF within blood vessels. Note the appearance of cuboid, elongated nuclei that typically morphologically
define endothelial cell nuclei (arrowheads). Rounder nuclei within the same regions most likely represent staining
of nuclei from pericytes. For Panel D, Case #3 was utilized, which had a confirmed APOE genotype of 4/4. All scale
bars represent 10 µm.

Em = 555/565) for the second label, both from
Invitrogen (Carlsbad, CA).
Statistical analysis
To determine the percent co-localization, quantitative analysis was performed as described
previously [19, 20] by taking 20X immunofluorescence, overlapping images from three differ940

ent fields in the hippocampus of four separate
VaD cases. Capturing was accomplished by
using a 2.5x photo eyepiece, a Sony high resolution CCD video camera (XC-77). As an example, to determine the percent co-localization
between nApoECF and PHF-1, photographs
were analyzed by counting the number of
nApoECF-, PHF-1-positive NFTs alone per 20X
Int J Clin Exp Pathol 2014;7(3):938-947
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Table 2. Relative distribution of nApoECF
labeling in VaD
Case
1
2
3
4
5
6
7

NFTs Reactive Astrocyts
+++
++
+++
+++
++
+
+++
++
+++
-

Blood Vessels
++
+++
+
++
+++
+++
+

(-) Denotes absence of any labeling with nApoECF.

field for each case, and the number of cells
labeled with both PHF-1 and nApoECF. Data are
representative of the average number (±S.D.) of
each antibody alone or co-localized with both
antibodies in each 20X field (3 fields total for 4
different cases). Statistical differences in this
study were determined using Student’s twotailed T-test employing Microsoft Office Excel.
Results
Cleaved apoE immunoreactive pathology
Previous characterization of the nApoECF antibody indicated that it is highly specific for an 18
kDa amino-terminal fragment of apoE [19]. This
in house antibody was synthesized based upon
a putative caspase-cleavage site (DADD) at
position D172 of the full-length protein. Application of this antibody to AD frontal cortex
brain sections revealed specific localization within neurofibrillary tangles (NFTs) that
was dependent upon the APOE genotype:
4/4≥3/4>3/3 [19]. However, in vitro cleavage
of apoE4 by caspase-3 to generate an 18 kDa
fragment detectable by the nApoECF antibody
was unsuccessful [19] and the protease
responsible for the in vivo cleavage of apoE4 is
unknown at this time. To determine if aminoterminal fragments of apoE can be detected in
VaD, an immunohistochemical study utilizing
the nApoECF antibody was performed utilizing
fixed hippocampal brain sections from seven
VaD cases. Case demographics for the VaD
cases used in this study are presented in Table
1. Notice that the APOE genotype was confirmed in all seven cases. All seven cases had a
primary neuropathological diagnosis of VaD
disease.
As an initial step, we screened all seven cases
for nApoECF immunoreactivity using bright-field
microscopy. Representative staining is depicted in Figure 1 indicating consistent labeling of
941

nApoECF within NFTs (arrows, Figure 1A), blood
vessels (Figure 1B), and within reactive astrocytes (Figure 1C). Labeling of nApoECF within
blood vessels was punctate and irregular
(Figure 1B and 1D). The relative intensity and
distribution of nApoECF in all seven cases is
shown in Table 2. It is noteworthy that the
nApoECF antibody cannot distinguish between
the three different isoforms of apoE and will
readily recognize the cleavage of apoE3 and E4
[19]. Although the general degree of nApoECF
immunoreactive pathology appeared to be
lower in those VaD cases defined as having
APOE genotype of 3/3, strong immunolabeling
was still observed in these cases (Table 2).
However, overall it did appear that those cases
determined to have the APOE genotype of
either 3/4 or 4/4 exhibited a greater degree of
nApoECF immunoreactive pathology (Table 2).
Full-length apoE4 immunoreactive pathology
Utilizing VaD Case #3 with a confirmed APOE
genotype if 4/4, we screened this case using
full-length antibodies to the N- or C-terminal
regions of the protein. Previous studies in AD
have indicated a preferential localization of
apoE4 antibodies such that N-terminal antibodies immunolabel both plaques and tangles, while C-terminal antibodies immunolabel
plaques only [21]. We confirmed these results
in VaD as depicted in Figure 2. Application of
the full-length N-terminal antibody to apoE4
indicated staining within both NFTs (arrows,
Figure 2A) and diffuse plaques (arrows, Figure
2B). In contrast, no staining within NFTs was
observed utilizing the full-length C-terminal antibody to apoE but strong labeling was
observed within blood vessels (Figure 2C). To
confirm the co-localization of the full-length
N-terminal antibody to apoE with our in house
cleavage apoE antibody, double-label immunofluorescence
studies
were
performed.
Co-localization of both antibodies was evident
within NFTs (Figure 2D-F). It is noteworthy that
the nApoECF antibody did not label extracellular plaques in any VaD cases, as also previously
demonstrated in the AD brain [19]. These data
suggest that extracellular plaques are composed principally of full-length apoE4.
Full-length apolipoprotein E immunoreactivity
co-localizes with beta-amyloid both extra- and
intracellularly
To confirm the presence of full-length apoE
within extracellular plaques, double-label immunofluorescence experiments were performed.
Int J Clin Exp Pathol 2014;7(3):938-947
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Figure 2. Characterization of apoE labeling in vascular disease utilizing full-length antibodies to both the C- and
N-terminals regions to apoE. For all panels, representative labeling is shown utilizing Case #3, which had a confirmed
APOE genotype of 4/4. (A and B) Representative staining following application of a full-length apoE antibody to
the amino-terminal region of apoE revealed labeling within both NFTs (arrows, A) and diffuse plaques (arrows, B).
(C) Identical to Panels A and B except for the use of a C-terminal full-length antibody to apoE indicating labeling
predominantly within blood vessels. (D-F) Double-label immunofluorescence experiment employing our in house
nApoECF antibody (green, D), amino-terminal full-length antibody to apoE (red, E), and the overlap image for the two
antibodies indicating co-localization within apparent NFTs (arrows, F). All scale bars represent 10 µm.

As shown in Figure 3, co-localization between
the full-length amino-terminal apoE4 antibody
and 6E10 was evident within extracellular
plaques in VaD (Figure 3A-C). A quantitative
analysis of this co-localization revealed that
approximately 76.5% of all beta-amyloid
plaques contained the full-length apoE protein
(Figure 3H). Besides plaques, co-localization of
6E10 and the full-length amino-terminal apoE
antibody was also evident within blood vessels
(Figure 3D), degenerating glial cells (Figure 3F),
and within occasional NFTs (Figure 3G).
Interesting, we also observed strong intracellular staining of the 6E10 antibody within neurons of the hippocampus that did not co-localize with the full-length apoE antibody (Figure
3E).
Co-localization of the amino-terminal fragment
apoE antibody with PHF-1, a marker for NFTs
Experiments were undertaken to determine the
extent of localization of the nApoECF antibody
within NFTs in VaD. As depicted in Figure 4, co-

942

localization between PHF-1 and nApoECF
was evident within NFTs predominantly within
layer II of the entorhinal cortex (Figure 4A-C).
Interesting, co-localization was primarily reserved in Stage 3 and 4 NFTs, in contrast to
Stage 2 NFTs that were only labeled with PHF-1
(Figure 3A-C). A quantitative analysis indicated
that approximately 38.4% of all identified PHFlabeled NFTs also labeled with the nApoECF
antibody (Figure 4E). Rarely, did we observe the
labeling of NFTs with the nApoECF antibody
alone (Figure 4E). In addition to NFTs, PHF-1
also strongly labeled neuritic plaques that consisted of large PHF-1 labeled strands (asterisk,
Figure 4D). These structures were never labeled
with the nApoECF antibody.
Identified NFTs in VaD were large and regionally localized to the entorhinal cortex
Application of the PHF-1 antibody in VaD
revealed labeling of large NFTs in layer II of the
entorhinal cortex (Figure 5A). It is possible that
these are stellate cells as they were often locat-

Int J Clin Exp Pathol 2014;7(3):938-947
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Figure 3. Distribution of beta-amyloid deposition in the vascular disease brain. (A-D) To confirm the presence of
plaques, double-immunofluorescence studies were carried out using an anti-beta-amyloid antibody, 6E10 (green, A)
together with a full-length amino-terminal antibody to apoE (red, B) with the overlap image shown in (C). The orange/
yellow fluorescence in Panel C depicts where the two antibodies co-localize within plaques. (D) is identical to Panels
A-C and depicts the labeling of apoE (arrows, yellow) predominantly within a blood vessel in which beta-amyloid
plaques (arrowheads, green) are closely associated with in proximity. Representative immunofluorescence labeling
in Panels A-D is shown utilizing Case #3, which had a confirmed APOE genotype of 4/4. (E-G) Besides plaques,
application of 6E10 also indicated the presence of beta-amyloid within neurons with Hoechst nuclear staining
(green, E, Case #4), degenerating glial cells (F, Case #1) and within NFTs (G, Case #1). Co-localization of 6E10 with
full-length amino-terminal antibody was evident both within glial cells (F) and NFTs (G). (H) Quantification of plaques
double-labeled by 6E10 and a full-length amino-terminal antibody to apoE. Data show the number of plaques labeled
with the full-length apoE antibody alone (blue bar), 6E10 alone (green bar) or those plaques that were labeled with
both antibodies (red bar). Plaques were identified in a 20X field within area CA1 by immunofluorescence overlap
microscopy (n=3 fields for 4 different Pick cases) ±S.D., *p<0.05. Data indicated that roughly 76.5% of all identified
plaques were labeled with both antibodies. All scale bars represent 10 µm except for Panel D, which represents 50
µm.

ed in entorhinal cortex islands. As a comparison to the size of NFTs found in VaD, PHF-1
labeling in a representative AD case is shown in
Figure 5B. To validate these structures were
indeed neuronal in nature, double-labeling experiments were carried out utilizing NeuN, a specific nuclear marker for neuronal cells.
Co-localization between PHF-1 and NeuN was
evident within large NFTs of the entorhinal cortex in the VaD brain (arrow, Figure 5C-E).
Discussion
VaD is the seconding leading cause of dementia in the USA [1], yet the causes of this form of
dementia remain largely nebulous. Clearly, risk
factors that increase the potential for strokes
or microbleeds including hypertension, hyperlipidemia, and artherosclerosis are also impor-
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tant risk factors for VaD [6-9]. One of the major
roles of apoE is to transport cholesterol in the
CNS, and therefore, it has been hypothesized
that loss of function of apoE may contribute to
a heightened risk for VaD as it does for AD [17].
In this manner, it has been hypothesized that
proteolytic cleavage of apoE may lead to loss of
function and functionally link the inheritance of
the APOE4 allele to the heightened risk for AD
[18]. Previous studies have indicated that apoE
is more susceptible to proteolytic cleavage
than the other isoforms of apoE [18]. However,
attempts to link APOE polymorphism to enhanced VaD risk have proven to be elusive as
conflicting reports have emerged (For example
see, [22-25]). Compounding these results is the
paucity of studies examining apoE pathology in
the VaD brain. Indeed, we were unable to

Int J Clin Exp Pathol 2014;7(3):938-947
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Figure 4. Co-localization of an amino-terminal fragment of apoE within NFTs of the vascular disease brain. (A-C)
Representative immunofluorescence double-labeling in Case #1 identified as having an APOE genotype of 3/4.
Utilizing the nApoECF antibody (green, Panel A) and PHF-1 (red, Panel B) revealed strong co-localization of the two
antibodies within a NFT located in the entorhinal cortex (Panel C). Arrow in Panel C denotes a single-labeled tangle
displaying vesicular punctate labeling with PHF-1 only. (D) Identical to Panel C illustrating co-localization of a single
NFT (arrowhead) as well as the single-labeled, large NFT labeled with PHF-1 only. In addition, a neuritic plaque
consisting of large PHF-1 labeled strands was evident within the field (asterisk, D). The representative staining
shown in Panel D was accomplished using Case #6, which had a confirmed APOE genotype of 3/4. (E) Quantification
of NFTs double-labeled by PHF-1 and nApoECF. Data show the number of NFTs labeled with nApoECF alone (blue
bar), PHF-1 alone (green bar) or those NFTs that were labeled with both antibodies (red bar). NFTs were identified
in a 20X field within hippocampal tissue sections by immunofluorescence overlap microscopy (n=3 fields using four
different VaD cases) ±S.D., *p<0.05. Data indicated that roughly 38.4% of all identified NFTs were labeled with both
antibodies. All scale bars represent 10 µm.

uncover a single study of apoE pathology in the
VaD brain after an exhaustive literature search.
Therefore, the primary purpose of this study
was to examine apoE immunoreactive pathology in VaD utilizing a custom, in house antibody
to the amino-terminal fragment of apoE as well
as full-length antibodies.
Screening seven pathologically confirmed
cases of VaD (Table 1) with our nApoECF antibody revealed three consistent staining features: 1) punctate labeling within blood vessels;
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2) labeling of late-stage tangles primarily in
layer II of the entorhinal cortex; 3) staining of
reactive astrocytes. The staining within blood
vessels was the most consistent finding utilizing the nApoECF antibody (Table 2) and suggests that cleavage of apoE within blood vessels could disrupt normal cholesterol transport
and therefore, contribute to the cerebral vascular disease observed in this disease. Staining
within reactive astrocytes may be indicative of
the strong inflammatory component that has
been associated with VaD [26]. In addition, a

Int J Clin Exp Pathol 2014;7(3):938-947
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Figure 5. Presence of large, stellate neurofibrillary tangles in layer II of the entorhinal cortex in vascular dementia. (A,
a and b) Representative single-label staining from VaD Case #1, showing staining in very large tangle-like structures
in layer II of the entorhinal cortex. (B) As a comparison, the relative size of NFTs from an AD subject are shown
following staining with PHF-1. Note the large size differential between the two types of tangles (Panel A vs. Panel B).
(C-E) Double-label immunofluorescence experiments in VaD Case #1 utilizing the neuronal marker, NeuN, (green, C)
together with PHF-1 (red, D), with the overlap image (arrow, E). All scale bars represent 10 µm.

previous study has documented the presence
of extensive gliosis in the VaD brain supporting
our current findings [27]. The finding of nApoECF
within NFTs was not surprising, as this antibody
strongly labels NFTs in the AD brain [19]. The
localization of the nApoECF within NFTs was
confirmed following co-localization experiments
with PHF-1. In general, we observed three to
four times less tangles in VaD as compared to
AD. Thus, in a previous study we documented
the presence of approximately 20-25 PHF-1labeled neurons per 20X field [19] as compared
to the current study whereby only 6-7 PHF-1labeled neurons were documented (Figure 4E).
Another interesting feature of PHF-1 labeling
were the large size of neurons stained within
clusters of layer II in the entorhinal cortex.
These cells most likely are stellate neurons representing an early stage in tangle pathology as
has been previously described in Down’s syndrome [28]. The extent of co-localization
between our nApoECF antibody and PHF-1 was
only 38%. This value was much lower for the
co-localization of the same two antibodies in
AD, which we have previously reported to be
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60%. The overall low percent co-localization
would suggest that the cleavage of apoE and
tangle pathology is poorly correlated as supported by a calculated Pearson coefficient of
0.27.
To verify the localization of our nApoECF antibody within NFTs, co-localization experiments
were carried out using full-length antibodies to
either the N- or C-terminal regions of apoE. As
expected, we confirmed the co-localization of
our in house antibody with the full-length
N-terminal antibody but not the C-terminal antibody to apoE. Application of the full-length
N-terminal apoE antibody to VaD cases also
revealed strong immunolabeling within extracellular plaques that co-localized with an antibeta-amyloid antibody, 6E10. An interesting
feature of the nApoECF antibody is that it does
not label extracellular plaques in the AD brain
[19], nor did it label plaques observed in VaD.
These data suggest that extracellular plaques
consist primarily of full-length apoE, moreover,
the presence of cleaved apoE within NFTs supports the hypothesis that the cleavage event of

Int J Clin Exp Pathol 2014;7(3):938-947
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apoE occurs intracellularly or within blood vessels, but not in the extracellular compartment.
A final observation regarding apoE in the VaD
brain that was shown in the present study was
the staining of the nApoECF antibody in cases
that had known genotypes of 3/3. Human apoE
is polymorphic with three major isoforms,
apoE2, apoE3, and apoE4, which differ by single amino acid substitutions involving cysteinearginine replacements at positions 112 and
158 [16]. Our in house nApoECF antibody recognizes the N-terminal fragment of apoE in 3/3
and 3/4, and 4/4 genotypes [19]. In VaD, we
observed widespread staining of the nApoECF
in cases expressing all three different genotypes (Table 2). However, there appeared to be
a general trend for less apoE-immunoreactive
pathology in VaD cases with known genotypes
of 3/3 (Table 2). This is consistent with previous observations that apoE4 is highly susceptible to proteolysis compared to the other major
isoforms of apoE [29].
In conclusion, we have reported for the first
time the presence of cleaved apoE in the VaD
brain. The localization of an amino-terminal
fragment of apoE was determined to largely be
confined within NFTs, blood vessels, and reactive astrocytes. ApoE immunoreactive pathology was documented in all seven VaD cases
examined including those cases with a confirmed APOE genotype of 3/3. The presence of
cleaved apoE within the hippocampus of VaD
cases provides for pathological data supporting the potential link between APOE polymorphism and enhanced risk for VaD. In addition,
the potential loss of function of apoE following
cleavage may contribute to disease progression in a disorder whereby cerebral vascular
risk factors play such an important role.
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